Gsk Plc ADR
(NY:
GSK
)
43.91
+0.17 (+0.39%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gsk Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
33
34
Next >
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
August 23, 2024
Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite concerns, experts predict limited financial impact on companies like Pfizer,...
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
August 19, 2024
Via
Benzinga
Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk
August 16, 2024
A Florida State Court sided with GSK, dismissing expert testimonies that linked ranitidine to prostate cancer, reflecting a broader scientific consensus that there is no consistent evidence supporting...
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
August 15, 2024
Via
Benzinga
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
July 29, 2024
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Is GSK a Top-Value Stock Right Now?
July 17, 2024
GSK, a multinational pharma company, scans as a bargain.
Via
The Motley Fool
New European Regulations Could Hinder Rare Disease Treatments, Pharma Industry Raises Concerns Over Stricter Clinical Trial Rules
August 13, 2024
Pharmaceutical companies, researchers, and patient groups are voicing concerns over new EU regulations that could hinder rare disease treatment development by imposing stricter guidelines on medical...
Via
Benzinga
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
August 12, 2024
Via
Benzinga
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows
August 07, 2024
Via
Investor Brand Network
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
August 06, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Lucrative Incentive for Biotechs as Global Alzheimer’s Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
August 06, 2024
EQNX::TICKER_START (NYSE:ANVS),(NYSE:PFE),(NYSE:LLY),(NYSE:GSK),(NYSE:NVO) EQNX::TICKER_END
Via
FinancialNewsMedia
Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.
August 05, 2024
Moderna sustained a rare downgrade on Monday following its guidance cut for the year.
Via
Investor's Business Daily
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
August 02, 2024
Moderna cuts its 2024 sales forecast due to weaker demand for COVID-19 vaccines. Sales now expected between $3B-$3.5B, down from $4B. Analysts adjust price targets, citing competitive pressures from...
Via
Benzinga
Exposures
COVID-19
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
August 06, 2024
From
FN Media Group LLC
Via
GlobeNewswire
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
August 01, 2024
From
GSK plc
Via
Business Wire
Tech Stocks On Track For Best Session In 5 Months Ahead Of Fed Meeting; Small Caps Target Highest Close Since January 2022: What's Driving Markets Wednesday?
July 31, 2024
Tech stocks soared to their best session in five months on Wednesday, ahead of the highly anticipated Federal Open Market Committee (FOMC) meeting.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
British Pharma Giant GSK's Blockbuster Shingles And Respiratory Syncytial Virus Vaccine Q2 Sales Miss Expectations, Cuts Annual Vaccine Revenue Guidance
July 31, 2024
GSK reported Q2 sales of $9.95 billion, beating estimates of $9.66 billion. Specialty Medicine sales rose 20%, driven by strong HIV, Respiratory/Immunology, and Oncology performance. Core EPS of $1.10...
Via
Benzinga
Topics
Earnings
Exposures
Financial
GSK Beats Second-Quarter Views, Raises Outlook; But Shares Fall On Shingrix Miss
July 31, 2024
The company, however, raised its sales and earnings outlook for the year.
Via
Investor's Business Daily
Wall Street Remains On Track For AMD-Led Rebound Ahead Of Fed Decision, Meta Earnings: Analyst Says 'The Bull Tends To Remain' Despite Near-Time Volatility
July 31, 2024
Tech optimism is likely to abound on Wall Street as AI-levered stocks are feeding off the strength generated by Advanced Micro Devices, Inc.‘s (NASDAQ:AMD)
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
GSK Stock Earnings: GSK Beats EPS, Beats Revenue for Q2 2024
July 31, 2024
GSK stock results show that GSK beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
GSK's Top Selling Vaccine Can Potentially Reduce Dementia Risk, Research Suggests
July 26, 2024
New research suggests that GSK's Shingrix vaccine may reduce dementia risk, potentially revolutionizing treatment for older adults. The study, involving 200,000 people, indicates a significant...
Via
Benzinga
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
July 23, 2024
ViiV Healthcare's Dovato matches Gilead's Biktarvy in effectiveness for HIV treatment. The study reveals Dovato's benefit of less weight gain compared to Biktarvy, highlighting its efficacy and patient...
Via
Benzinga
3 Stocks Under $10 With the Potential for Massive Gains
July 22, 2024
Discover the growth potential of top small-cap stocks in the consumer finance, healthcare equipment and pharmaceutical industries.
Via
InvestorPlace
Top Research Reports For Apple, Lowe's & Shopify
July 17, 2024
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc., Lowe's Companies, Inc., and Shopify Inc., as well as two micro-cap stocks MIND Technology, Inc., and...
Via
Talk Markets
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
July 17, 2024
European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed.
Via
Benzinga
Exposures
COVID-19
3 Top Cancer Treatment Stocks to Buy Now
July 17, 2024
These cancer treatment stocks are well-positioned to benefit tremendously from strong demand for their cancer treatments in the longer term.
Via
InvestorPlace
Positive News is Driving This Cancer Drug Maker’s Stock Higher
July 15, 2024
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather
Via
MarketBeat
The 3 Most Undervalued Pharma Stocks to Buy in July 2024
July 12, 2024
Pharma stocks can be great investments during times of growth and recession, and are made even better if the stock is undervalued.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season
July 11, 2024
From
GSK plc
Via
Business Wire
3 Dirt-Cheap Drug Developers With Blockbuster Potential
July 11, 2024
These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.